2023 ACIP Updates for Immunizations in Adults and Children: What ...
Anti-vaxxer In Chief? DeSantis Elevates Vaccine Skepticism To Marquee Campaign Issue
usatoday.Com cannot provide a good user experience to your browser. To use this site and continue to benefit from our journalism and site features, please upgrade to the latest version of Chrome, Edge, Firefox or Safari.
Dr. Peter McCullough On "The Holy Grail Of COVID-19 Vaccine Detoxification"
Dr. Peter McCullough has been a voice of reason in a medical system, deemed by some as, crazed by COVID-19 hysteria.
As a leading cardiologist, he worked to educate us all on what – and what isn't – the science behind COVID and the vaccines.
And his warnings about vaccines have been borne out.
In a recent article, Dr. McCullough said:
"Far and away, the most common question I get from those who took one of the COVID-19 vaccines is: 'How do I get this out of my body?' The mRNA and adenoviral DNA products were rolled out with no idea of how or when the body would ever break down the genetic code. The synthetic mRNA carried on lipid nanoparticles appears to be resistant to breakdown by human ribonucleases by design, so the product would be long-lasting and produce the protein product of interest for a considerable time period. It is a big problem when the protein is the pathogenic SARS-CoV-2 Spike.
This leaves the dissolution of Spike protein as a therapeutic goal for the vaccine injured. With the respiratory infection, Spike is processed and activated by cellular proteases, including transmembrane serine protein 2 (TMPRSS2), cathepsin and furin. With vaccination, these systems may be avoided by systemic administration and production of Spike protein within cells. As a result, the pathogenesis of vaccine injury syndromes is believed to be driven by the accumulation of Spike protein in cells, tissues and organs.
Nattokinase is an enzyme produced by fermenting soybeans with the bacteria Bacillus subtilis var. Natto and has been available as an oral supplement. It degrades fibrinogen, factor VII, cytokines and factor VIII and has been studied for its cardiovascular benefits. Of all the available therapies I have used in my practice and among all the proposed detoxification agents, I believe nattokinase and related peptides hold the greatest promise for patients now."
If you or someone you love needs nattokinase, The Wellness Company's "Spike Support Formula" contains nattokinase plus other extracts known to help the body recover from spike protein exposure – both from the vaccine and COVID-19.
In The Wellness Company's Spike Support Formula, you will find:
Here is Dr. Jen VanDeWater, PharmD, talking about the benefit of the combination of elements in The Wellness Company's Spike Support Formula:
What are people saying about The Wellness Company's Spike Support Formula:
"I saw Dr. McCullough talk about the product and decided to give it a try. A month and a half later, I feel so much better. I also have recommended the product to family members to help them detox from the painful side effects of the vaccine."
"I feel like I have had brain fog for the past 18 months, and after taking this supplement noticed the fog lifting finally. I plan to buy more for myself and now a friend suffering from heart issues."
"I am grateful for the Wellness Company and for you coming out with this spike protein vitamin. I am a big believer in natural healing and not pharmaceutical drugs. Thank you for doing what is right and for speaking the truth in a world that is so dark."
On The Wellness Company's website, you will see that purchasing all the individual components of the Spike Support Formula would be over $100. You save 36% with the unique formulation of The Wellness Company's Spike Support Formula.
Click here to order the Spike Support Formula today!
The opinions in this article do not necessarily reflect the opinions of the Las Vegas Review-Journal and you should consult your doctor before beginning any new health related practice.
Members of the editorial and news staff of the Las Vegas Review-Journal were not involved in the creation of this content.
Global Trial To Investigate Skin Cancer Vaccine/Immunotherapy Combo
A global trial recently launched that will investigate a personalized mRNA vaccine with Keytruda for patients with skin cancer.
Patients with skin cancer can now enroll in a late-stage clinical trial testing a personalized mRNA-based vaccine in combination with the immunotherapy agent, Keytruda (pembrolizumab), according to a joint announcement from Moderna, the manufacturer of the vaccine, and Merck, the manufacturer of Keytruda.
Researchers plan on enrolling more than 1,000 patients with melanoma whose tumors were surgically removed. The main goal of the study — which will be conducted in more than 20 countries — is to determine if vaccine/immunotherapy combination improves the amount of time patients live without their cancer returning, (a statistic known as recurrence-free survival). Outcomes will be compared among two groups: some patients will receive the vaccine plus Keytruda, while others will receive Keytruda alone.
Prior findings from the phase 2b mRNA-4157-P201/KEYNOTE-942 trial demonstrated promise with the vaccine/immunotherapy combination. In fact, giving the two together led to a 44% reduction in the risk of death or recurrence in patients with high-risk, resected melanoma, according to findings presented at the 2023 AACR Annual Meeting.
READ MORE: Cancer Vaccine Combo a 'Potential Major Breakthrough' in Skin Cancer
Additionally, data showed that at the 18-month mark, 78.6% of patients were alive and without disease recurrence in the vaccine/Keytruda group, compared with 62.2% in the Keytruda-only group.
The investigational vaccine works similarly to COVID-19 vaccines, in that it is mRNA based. The personalized injection works by promoting the generation of T cells, which are a part of the immune system that fights off foreign invaders, such as cancer.
Keytruda also uses the patient's immune system by blocking certain proteins on the cancer cell surface that allow the tumors to hide from the immune system. When these proteins are no longer active, T cells can better find and attack the cancer.
This is not the only research regarding cancer vaccines that is currently ongoing. In a January 2023 interview with CURE®, one expert said, "I think that there's concerted efforts, both on the academic side and also on the industry side, to work on (cancer vaccines). … the signals are all in the positive."
Additionally, phase 1 study data that was published in the journal, Nature, showed that a personalized mRNA-based pancreatic cancer vaccine called autogene cevumeran — when given after surgery and Tecentriq (atezolizumab), and alongside a chemotherapy regimen — was successful in staving off cancer's return for 18 months in patients who had a strong T-cell response to the vaccine. Of note, Tecentriq is an immune checkpoint inhibitor that works similarly to Keytruda.
The study was small, with only 16 patients being treated with the investigational vaccine, and the researchers mentioned that more trials need to be conducted in this space.
"Here, we provided evidence that despite the low mutation rate of (pancreatic cancer), a mRNA vaccine can induce T cell activity against neoantigens in this cancer, a non-inflamed tumor with predominantly immune-excluded or desert phenotypes," the researchers wrote in their study. "Whether mRNA neoantigen vaccines can similarly activate T cells in other non-inflamed cancers should be more broadly tested."
For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.
Comments
Post a Comment